Gain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders.
Gain Therapeutics has raised $7.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.
Gain Therapeutics's investors include Innosuisse, 3B Future Health Fund, Eurostars, Horizon 2020, TiVentures.
Gain Therapeutics is headquartered in Bethesda, United States.
Gain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders.
Gain Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gain Therapeutics — Funding & Investors." VCBacked, July 16, 2025, https://www.vcbacked.co/company/gain-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Gain Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/gain-therapeutics
{{cite web |title=Gain Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/gain-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated